|
|
|
|
LEADER |
01946nam a22003015i 4500 |
001 |
000284635 |
005 |
20210817180908.0 |
007 |
cr nn 008mamaa |
008 |
170328s2017 gw | s |||| 0|eng d |
020 |
|
|
|a 9783319499697
|
024 |
7 |
|
|a 10.1007/978-3-319-49969-7
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Leucine-Rich Repeat Kinase 2 (LRRK2) /
|c edited by Hardy J. Rideout.
|
250 |
|
|
|a 1st ed. 2017.
|
260 |
# |
# |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2017.
|
300 |
|
|
|a XVII, 271 p. 27 illus., 17 illus. in color. :
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Advances in Neurobiology,
|v 14
|
505 |
0 |
|
|a Part I: Clinical and Genetic Considerations of LRRK2 Associated Parkinson’s Disease -- Leucine-rich repeat kinase (LRRK2) genetics and Parkinson’s disease -- Clinical features of LRRK2 carriers with Parkinson’s disease -- Part II: Fundamentals of LRRK2 Biology -- LRRK2 phosphorylation -- Understanding the GTPase activity of LRRK2: regulation, function and neurotoxicity -- LRRK2 and autophagy -- Molecular insights and functional implication of LRRK2 dimerization -- LRRK2 and the immune system -- Regulation of LRRK2 by phosphatases -- Part III: LRRK2 Neurodegeneration, Modeling, and Therapeutic Options -- Animal models of LRRK2-associated Parkinson’s disease -- LRRK2 and the “LRRKtosome” at the crossroads of programmed cell death: Clues from RIP kinase relatives -- Interaction of LRRK2 and α-synuclein in Parkinson’s disease -- Mechanisms of mutant LRRK2 neurodegeneration -- Small molecule inhibitors of LRRK2.
|
650 |
|
0 |
|a Neurosciences.
|
650 |
|
0 |
|a Neurology .
|
650 |
1 |
4 |
|a Neurosciences.
|
650 |
2 |
4 |
|a Neurology.
|
700 |
1 |
|
|a Rideout, Hardy J.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|